Q2 Earnings Forecast for VRTX Issued By William Blair

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - Research analysts at William Blair issued their Q2 2025 EPS estimates for shares of Vertex Pharmaceuticals in a note issued to investors on Tuesday, May 6th. William Blair analyst M. Minter anticipates that the pharmaceutical company will post earnings of $3.95 per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is $15.63 per share. William Blair also issued estimates for Vertex Pharmaceuticals' Q3 2025 earnings at $4.16 EPS and Q4 2025 earnings at $4.54 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Vertex Pharmaceuticals's revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm earned $4.76 earnings per share.

Several other brokerages also recently weighed in on VRTX. Cantor Fitzgerald restated an "overweight" rating and set a $535.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Morgan Stanley lifted their price target on shares of Vertex Pharmaceuticals from $462.00 to $464.00 and gave the company an "equal weight" rating in a report on Tuesday, May 6th. Needham & Company LLC reiterated a "hold" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Scotiabank lowered their target price on Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating for the company in a report on Tuesday, May 6th. Finally, Bank of America upped their price objective on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Thirteen investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $515.04.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX traded up $0.54 on Thursday, hitting $439.91. 1,662,338 shares of the company's stock were exchanged, compared to its average volume of 1,395,263. Vertex Pharmaceuticals has a 52 week low of $377.85 and a 52 week high of $519.88. The stock has a 50-day moving average of $487.70 and a 200-day moving average of $465.56. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The stock has a market cap of $112.97 billion, a price-to-earnings ratio of -199.96, a P/E/G ratio of 2.11 and a beta of 0.51.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Several hedge funds have recently bought and sold shares of VRTX. Quent Capital LLC grew its position in Vertex Pharmaceuticals by 4.5% during the first quarter. Quent Capital LLC now owns 513 shares of the pharmaceutical company's stock valued at $249,000 after acquiring an additional 22 shares during the last quarter. Truvestments Capital LLC boosted its position in Vertex Pharmaceuticals by 30.3% during the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock valued at $40,000 after buying an additional 23 shares during the period. Advisor OS LLC grew its stake in shares of Vertex Pharmaceuticals by 4.4% during the first quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company's stock valued at $263,000 after buying an additional 23 shares during the last quarter. Simon Quick Advisors LLC increased its holdings in shares of Vertex Pharmaceuticals by 1.1% in the fourth quarter. Simon Quick Advisors LLC now owns 2,236 shares of the pharmaceutical company's stock worth $900,000 after buying an additional 24 shares during the period. Finally, Spinnaker Trust lifted its stake in shares of Vertex Pharmaceuticals by 2.1% in the 4th quarter. Spinnaker Trust now owns 1,235 shares of the pharmaceutical company's stock valued at $497,000 after acquiring an additional 25 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Insider Activity at Vertex Pharmaceuticals

In other news, EVP David Altshuler sold 3,231 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the transaction, the executive vice president now owns 26,512 shares of the company's stock, valued at approximately $13,256,000. This represents a 10.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Ourania Tatsis sold 530 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $475.34, for a total value of $251,930.20. Following the sale, the executive vice president now directly owns 58,539 shares of the company's stock, valued at $27,825,928.26. This represents a 0.90% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,005 shares of company stock worth $1,978,465. 0.20% of the stock is owned by company insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.